Clinical trial · Observational
Met Non Small Cell Cancer Registry (MOMENT)
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Advanced Non-small Cell Lung Cancer with METex14 skipping alterations
- description
- Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
Primary outcomes (5)
- measure
- Best Overall Response (BOR)
- timeFrame
- Through study completion, up to approximately 4.9 years
- measure
- Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
- timeFrame
- Up to approximately 4.9 years
- measure
- Overall Survival (OS)
- timeFrame
- Through study completion, up to approximately 4.9 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Participants who signed ICF * Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay) * Participants who are starting or are already being treated with systemic therapy Exclusion Criteria: * Participants who are enrolled in a clinical trial
References
Publications (1)
- DERIVEDThomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21. PMID 39836056